- Trials with a EudraCT protocol (739)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (57)
739 result(s) found for: Interferon.
Displaying page 1 of 37.
EudraCT Number: 2009-013284-19 | Sponsor Protocol Number: HINABS-ITI | Start Date*: 2009-12-10 |
Sponsor Name:Medical University Innsbruck | ||
Full Title: Immune tolerance induction in MS patients with neutralizing antibodies against interferon-beta | ||
Medical condition: multiple sclerosis patients with neutralizing antibodies against interferon-beta | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-016678-34 | Sponsor Protocol Number: CRO1456 | Start Date*: 2010-04-15 |
Sponsor Name:Imperial College London | ||
Full Title: Exploring the Relationship Between Insulin Resistance and Interferon Resistance: Options to Overcome HCV Non-Response to Pegylated Interferon | ||
Medical condition: HCV infected patient who do not response to Pegylated Interferon. This study is trying to explore the relationship between insulin resistance and Interferon Resistance and the possible rule of Pio... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-001008-37 | Sponsor Protocol Number: Bab1 | Start Date*: 2005-11-01 |
Sponsor Name:Sahlgrenska University Hospital | ||
Full Title: Analysis of the antibody level against interferon beta before and after increase of dose in MS therapy | ||
Medical condition: Multiple sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-003570-89 | Sponsor Protocol Number: 37559 | Start Date*: 2011-12-02 | |||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||
Full Title: The effect of interferon beta-1a treatment on functional adaptation in Multiple Sclerosis (MS) | |||||||||||||
Medical condition: Multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000029-31 | Sponsor Protocol Number: GIPF-007 | Start Date*: 2005-01-28 |
Sponsor Name:InterMune | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon gamma-Ib in patients with Idiopathic Pulmonary Fibrosis The INSPIRE Trial - International Stu... | ||
Medical condition: Idiopathic Pulmonary Fibrosis (IPF) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-005751-18 | Sponsor Protocol Number: QS001 | Start Date*: 2006-09-07 |
Sponsor Name:UCL Biomedicine R&D Unit | ||
Full Title: A multi-centre randomised study to evaluate the efficacy of Betaferon-interferon-beta-1b (IFNB-1B) 500 mcg therapy in the induction of tolerance to IFNB in MS patients with neutralising antibodies ... | ||
Medical condition: Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system of unknown aetiology. It is the commonest cause of disability in young adults. The prevalence in the U... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-005450-30 | Sponsor Protocol Number: ABI-MS-P01 | Start Date*: 2014-01-08 |
Sponsor Name:Medizinische Universität Innsbruck | ||
Full Title: Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk of immunization in multiple sclerosis patients on interferon-beta treatment | ||
Medical condition: Development of neutralising antibodies against Interferon-beta in the treatment of multiple sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-006208-52 | Sponsor Protocol Number: IFN005 | Start Date*: 2009-03-09 | |||||||||||
Sponsor Name:Helix BioPharma Cooperation | |||||||||||||
Full Title: Mono-centre, open-label study to investigate the multi-dose pharmacokinetics, efficacy and safety of Interferon alpha-2b Cream in women with a history of cytological diagnosed Pap IIID, with a con... | |||||||||||||
Medical condition: cervical dysplasia (CIN I or CIN II; Pap IIID in the history, confirmed HPV+ status) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016824-29 | Sponsor Protocol Number: 1232009 | Start Date*: 2010-04-06 | |||||||||||
Sponsor Name:Dansk Multipel Sclerose Center | |||||||||||||
Full Title: REsPons på interferon-Alfa hos InterfeRon-β-neutraliserende antistof-positive patienter med multipel sklerose | |||||||||||||
Medical condition: Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005545-20 | Sponsor Protocol Number: IJBNMDOCASTOR | Start Date*: 2014-12-23 | |||||||||||
Sponsor Name:Institut Jules Bordet | |||||||||||||
Full Title: The CaStOR study Carcinoid Tumors after failure of Somatostatin analogs: a randomized phase III of Octreotide Lutate Peptid Receptor radionuclide Therapy (PRRT) versus inteRferon α-2b | |||||||||||||
Medical condition: Progressive, unresectable, non-pancreatic gastrointestinal neuroendocrine tumors resistant to therapy with somatostatin analogues. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006333-27 | Sponsor Protocol Number: 105MS301 | Start Date*: 2009-06-19 | |||||||||||
Sponsor Name:Biogen Idec LTD | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ... | |||||||||||||
Medical condition: Relapsing Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) EE (Completed) DE (Completed) BE (Completed) NL (Completed) ES (Completed) CZ (Completed) BG (Completed) GR (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000453-37 | Sponsor Protocol Number: 3179/AO/14 | Start Date*: 2014-12-16 |
Sponsor Name:Azienda Ospedaliera di Padova | ||
Full Title: Sequential treatment with nucleotide analogue and peg-interferon in patients with HBV-related chronic hepatitis. | ||
Medical condition: Hepatitis B virus (HBV) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001012-19 | Sponsor Protocol Number: CFTY720DNL02T | Start Date*: 2014-12-17 |
Sponsor Name:VU University Medical Center | ||
Full Title: Effects of fingolimod on functional brain adaptation and clinical measures in multiple sclerosis | ||
Medical condition: Relapsing-remitting (RR) multiple sclerosis (MS) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-004040-30 | Sponsor Protocol Number: EOC.NSI.11.01 | Start Date*: 2013-05-24 |
Sponsor Name:Ospedale Regionale di Lugano | ||
Full Title: Natalizumab de-escalation to interferon-beta-1b in patients with relapsing-remitting multiple sclerosis: A multicenter study | ||
Medical condition: relapse-remitting multiple sclerosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-003729-27 | Sponsor Protocol Number: 0.8 | Start Date*: 2013-11-15 |
Sponsor Name:Queen Mary University of London | ||
Full Title: Telaprevir in patients with genotype 3 HCV : pilot clinical study to evaluate efficacy and predictability of therapy in patients who have failed to respond to pegylated interferon and ribavirin | ||
Medical condition: Genotype 3 HCV | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-001419-21 | Sponsor Protocol Number: TPVAHC2012 | Start Date*: 2013-08-15 |
Sponsor Name:Universitätsklinikum Bonn | ||
Full Title: An open label, randomised, non-inferiority trial of pegylated interferon, ribavirin and telaprevir versus pegylated interferon and ribavirin alone in the response guided treatment of acute hepatiti... | ||
Medical condition: Acute Hepatitis C in HIV co-infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-001367-13 | Sponsor Protocol Number: IASO_MF | Start Date*: 2014-08-08 | |||||||||||
Sponsor Name:Medizinische Universtät Wien, Universitätsklinik für Innere Medizin I | |||||||||||||
Full Title: An open-label, prospective, single-centre, phase II study to assess dose and dose interval requirements with respect to efficacy and safety of AOP2014, PEG-Proline-Interferon alpha-2b, in patients ... | |||||||||||||
Medical condition: Primary Myelofibrosis (grade MF-0 and MF-1) according to the WHO criteria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000434-21 | Sponsor Protocol Number: PRT-PEG-15-10880 | Start Date*: 2016-11-14 | |||||||||||
Sponsor Name:Biogen Portugal | |||||||||||||
Full Title: PLENO – Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients with Relapsing Remitting Multiple Sclerosis (MS) Transitioning from Current... | |||||||||||||
Medical condition: Relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000282-35 | Sponsor Protocol Number: BO17705 | Start Date*: 2004-09-29 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A randomised, double-blind phase III study to evaluate the efficacy and safety of bevacizumab in combination with interferon alfa-2a (Roferon) versus interferon alfa-2a and placebo as first line tr... | |||||||||||||
Medical condition: Metastatic clear cell renal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000162-40 | Sponsor Protocol Number: IFN 001 | Start Date*: 2005-09-06 |
Sponsor Name:Helix Product Development (Ireland) Limited | ||
Full Title: Treatment of genital warts with Interferon alpha-2b Cream: a randomized, double blind, placebo-controlled study | ||
Medical condition: Condylomata acuminata (genital warts) | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Completed) DE (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
